Literature DB >> 1646599

The murine haemopexin receptor. Evidence that the haemopexin-binding site resides on a 20 kDa subunit and that receptor recycling is regulated by protein kinase C.

A Smith1, S M Farooqui, W T Morgan.   

Abstract

Haemopexin receptors from mouse hepatoma (Hepa) cells were affinity-labelled by cross-linking to haem-125I-haemopexin complexes using two homo-[disuccinimidyl suberate (DSS) and 3,3'-dithiobis(succinimidyl propionate) (DTSSP)] and one hetero-[sulphosuccinimidyl 4-(p-maleimidophenyl)butyrate (sulpho-SMPB)] bifunctional cross-linking agents. Analysis of the cross-linked products by SDS/PAGE in the absence of reducing agents revealed that 125I-haemopexin was cross-linked specifically to a protein of apparent molecular mass 85-90 kDa. Upon reduction, haemopexin remained cross-linked to a protein of 20 kDa, suggesting that the murine haemopexin receptor has a subunit structure. Two subunits were identified: alpha (p65) and beta (p20). Furthermore, because haemopexin was cross-linked by all three agents to p20, the shortest cross-linker arm being 1.1 nm (11 A), we propose that the haem-haemopexin-binding site resides on this subunit. In addition, a cysteine residue of p20 is located near the haemopexin-binding site, since haemopexin, which has no free thiol groups, is cross-linked to this subunit by the hetero-bifunctional agent sulpho-SMPB. Exposure of Hepa cells to the tumour-promoting phorbol ester 4 alpha-phorbol 12-myristate 13-acetate (PMA) causes a rapid redistribution of haemopexin receptors from the cell surface to the cell interior. Within 2-4 min of incubation with 100 nM-PMA, there was an approx. 50% decrease in cell-surface haemopexin receptors, as judged by ligand binding at 0 degrees C and affinity labelling of the receptor. This time- and dose-dependent down-regulation was fully reversible within 60-90 min after removal of PMA, and the affinity of the remaining receptors was unaltered by PMA. The specificity of PMA was demonstrated by comparison with the non-tumour-promoter 4 alpha-phorbol, which did not affect any of the parameters examined. The amine H-7, a specific inhibitor of protein kinase C, antagonised the receptor redistribution effect of PMA, suggesting that the down-regulation of haemopexin receptors on the cell surface was a consequence of protein kinase C activation. The PMA-induced decrease in surface haemopexin receptors was due to a 2-fold increase in the rate of internalization (from 0.73 min-1 to 1.32 min-1), whereas the rate of exocytosis (0.6 min-1) was unchanged. PMA treatment, like binding of the natural ligand, haem-haemopexin, results in a lower steady-state level of surface haemopexin receptors independent of receptor synthesis, and the receptors were not degraded but were recycled back to the cell surface.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646599      PMCID: PMC1151108          DOI: 10.1042/bj2760417

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

Review 1.  Oxidants and human disease: some new concepts.

Authors:  B Halliwell
Journal:  FASEB J       Date:  1987-11       Impact factor: 5.191

2.  Isolation of the hemopexin receptor from human placenta.

Authors:  S Taketani; H Kohno; Y Naitoh; R Tokunaga
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

3.  Endocytosis and control of expression of transferrin receptor.

Authors:  R C Hunt
Journal:  Dev Comp Immunol       Date:  1986       Impact factor: 3.636

4.  Regulation by phorbol esters of asialoglycoprotein and transferrin receptor distribution and ligand affinity in a hepatoma cell line.

Authors:  R J Fallon; A L Schwartz
Journal:  J Biol Chem       Date:  1986-11-15       Impact factor: 5.157

5.  Cell surface receptor for hemopexin in human leukemia HL60 cells. Specific binding, affinity labeling, and fate of heme.

Authors:  S Taketani; H Kohno; R Tokunaga
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

6.  Receptor-mediated heme uptake from hemopexin by human erythroleukemia K562 cells.

Authors:  S Taketani; H Kohno; R Tokunaga
Journal:  Biochem Int       Date:  1986-08

7.  Isolation of the haemopexin-haem receptor from pig liver cells.

Authors:  R Majuri; R Gräsbeck
Journal:  FEBS Lett       Date:  1986-04-07       Impact factor: 4.124

8.  Expression of the haemopexin-transport system in cultured mouse hepatoma cells. Links between haemopexin and iron metabolism.

Authors:  A Smith; B E Ledford
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

9.  Kinetics of insulin receptor internalization and recycling in adipocytes. Shunting of receptors to a degradative pathway by inhibitors of recycling.

Authors:  S Marshall
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

10.  Hemopexin joins transferrin as representative members of a distinct class of receptor-mediated endocytic transport systems.

Authors:  A Smith; R C Hunt
Journal:  Eur J Cell Biol       Date:  1990-12       Impact factor: 4.492

View more
  5 in total

Review 1.  Trafficking of heme and porphyrins in metazoa.

Authors:  Scott Severance; Iqbal Hamza
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

2.  Novel heme-binding component in the serum of the channel catfish (Ictalurus punctatus).

Authors:  G Massad; J E Arceneaux; B R Byers
Journal:  Biometals       Date:  1992       Impact factor: 2.949

Review 3.  Mammalian iron transport.

Authors:  Gregory Jon Anderson; Christopher D Vulpe
Journal:  Cell Mol Life Sci       Date:  2009-05-31       Impact factor: 9.261

4.  Identification and characterization of an iron-regulated hemopexin receptor in Haemophilus influenzae type b.

Authors:  J C Wong; J Holland; T Parsons; A Smith; P Williams
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

5.  Overexpression of hemopexin in the diabetic eye: a new pathogenic candidate for diabetic macular edema.

Authors:  Cristina Hernández; Marta Garcia-Ramírez; Rafael Simó
Journal:  Diabetes Care       Date:  2013-04-25       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.